Source and Illumina team up to develop DNA-based cancer prognostic
This article was originally published in Clinica
Executive Summary
UK DNA diagnostics firm Source BioScience is collaborating with gene sequencing specialist Illumina (San Diego, California) and Barts Cancer Institute in London to develop a genetic test to characterise tumours. The tool could improve the accuracy of cancer diagnosis and help identify the best treatment for individual patients.